1. Home
  2. TISI vs CRDF Comparison

TISI vs CRDF Comparison

Compare TISI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TISI

Team Inc.

HOLD

Current Price

$17.29

Market Cap

77.7M

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$0.95

Market Cap

86.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TISI
CRDF
Founded
1973
1999
Country
United States
United States
Employees
6800
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.7M
86.8M
IPO Year
1995
2012

Fundamental Metrics

Financial Performance
Metric
TISI
CRDF
Price
$17.29
$0.95
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
6.4K
1.6M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
$896,483,000.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.19
49.61
52 Week Low
$12.34
$0.76
52 Week High
$19.99
$3.31

Technical Indicators

Market Signals
Indicator
TISI
CRDF
Relative Strength Index (RSI) 52.28 N/A
Support Level $16.62 N/A
Resistance Level $17.10 N/A
Average True Range (ATR) 0.73 0.00
MACD 0.02 0.00
Stochastic Oscillator 48.93 0.00

Price Performance

Historical Comparison
TISI
CRDF

About TISI Team Inc.

Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: